This invention relates to treating and preventing urinary tract infections. Glycerol monolaurate (GML) and/or GML-related compositions together with suitable accelerants in gel-based formulation may be used to treat urinary tract infections that may be generally diagnosed, for example, in women, catheterized patients and elderly individuals. Such a gel-based formulation kills, or inhibits the growth of, one or more pathogenic microorganisms that cause urinary tract infections.

The present invention relates to the technical field of medical devices, in particular to a drug coating, a drug-coated balloon and a preparation method thereof. The drug coating comprises a drug active coating and a positively-charged hydrophobic modified layer which are sequentially attached to the surface of a substrate. By providing the positively charged hydrophobic modified layer comprising the positively-charged modified substance and the hydrophobic substance, the entire surface of the drug coating is given positive electric charge and hydrophobic property. Such positive electric charge characteristics make the drug coating can be strongly combined with the negatively-charged inner wall of blood vessels, so that the drug coating can be permanently adsorbed on the inner wall of blood vessels. The combination of positive electric charge characteristics and hydrophobic property can effectively resist the influence of blood flow on the erosion of drug coating during transportation.

A process for making lipid-coated substrates including the steps of a. providing a lipid solution (A) of phospholipids in a water miscible organic solvent at a phospholipid concentration between 25 and 450 mg/ml; b. provide an aqueous solution (B) having pH between 4 and 8; c. agitate the aqueous solution (B) and dispense the lipid solution (A) into the aqueous solution (B) to prepare an aqueous dispersion including lipid vesicles (C) having a number average size between 80 and 120 nm (measured according to dynamic light scattering) at a phospholipid concentration between 0.05 mg/ml and 2 mg/ml; and d. applying the aqueous dispersion (C) to a substrate and formation of a lipid-based coating; wherein aqueous dispersion (C) contains at least 95 wt. % water. Medical devices including a lipid-based coating, for example contact lenses and catheters.

A cured non-polymeric gel including a plurality of non-polymeric cross-links. The non-polymeric cross-links result from curing an oil or oil composition at selected curing conditions to achieve a desired amount of cross-linking to form the non-polymeric gel. The desired amount of cross-linking is selected based on a desired rate of degradation of the gel after the gel is implanted. The oil or oil composition comprises one or more of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or alpha-linolenic acid (ALA).

A cured non-polymeric gel including a plurality of non-polymeric cross-links. The non-polymeric cross-links result from curing an oil or oil composition at selected curing conditions to achieve a desired amount of cross-linking to form the non-polymeric get. The desired amount of cross-linking is selected based on a desired rate of degradation of the gel after the gel is implanted. The oil or oil composition comprises one or more of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or alphalinolenic acid (ALA).

The invention provides a novel approach to controlled delivery of biomolecules (e.g., lipids and proteins) by employing novel amphiphilic polymers that are effective delivery vehicles. These unique amphiphilic polymers may be employed as controlled delivery vehicles or tissue engineering scaffolds wherein the delivery of lipophilic or amphiphilic bioactive molecules can be achieved. An amphiphilic biodegradable polymer platform is disclosed herein for the stable encapsulation and sustained release of biomolecules, such as S1P.

A wound management system can comprise a surgically acceptable adhesive disposed over a wound and a surgically acceptable film repositionably disposed over the surgically acceptable adhesive, and methods of managing a wound involving the same.

The present invention relates to absorbent articles comprising species of glyceride copolymers that provide unexpectedly improved softening performance and formulability.

Provided is a malleable implant configured to fit at or near a bone defect site to promote bone growth, the malleable implant comprising: a biodegradable polymer, mineral particles, and an oxysterol, the implant configured to become moldable upon being wetted with a fluid. Methods of making and use are further provided.

Provided is a lyophilized implant configured to fit at or near a bone defect to promote bone growth, the lyophilized implant containing a biodegradable polymer in an amount of about 0.1 wt. % to about 20 wt. % of the implant, mineral particles in an amount from about 0.1 wt. % to about 75 wt. % of the implant, and an oxysterol in an amount of about 5 wt. % to about 90 wt. % of the implant. Methods of making and using the implant are further provided.